COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option?

S-Y Sheu; F Grabellus; S Schwertheim; K Mann; C Ensinger; D Ofner; Maximilian Bockhorn; D Fuhrer; K W Schmid

COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option?

Standard

COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option? / Sheu, S-Y; Grabellus, F; Schwertheim, S; Mann, K; Ensinger, C; Ofner, D; Bockhorn, Maximilian; Fuhrer, D; Schmid, K W.

In: HORM METAB RES, Vol. 41, No. 4, 4, 2009, p. 314-319.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Sheu, S-Y, Grabellus, F, Schwertheim, S, Mann, K, Ensinger, C, Ofner, D, Bockhorn, M, Fuhrer, D & Schmid, KW 2009, 'COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option?', HORM METAB RES, vol. 41, no. 4, 4, pp. 314-319. <http://www.ncbi.nlm.nih.gov/pubmed/19048457?dopt=Citation>

APA

Sheu, S-Y., Grabellus, F., Schwertheim, S., Mann, K., Ensinger, C., Ofner, D., Bockhorn, M., Fuhrer, D., & Schmid, K. W. (2009). COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option? HORM METAB RES, 41(4), 314-319. [4]. http://www.ncbi.nlm.nih.gov/pubmed/19048457?dopt=Citation

Vancouver

Sheu S-Y, Grabellus F, Schwertheim S, Mann K, Ensinger C, Ofner D et al. COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option? HORM METAB RES. 2009;41(4):314-319. 4.

Bibtex

@article{d6c494261c2c4a7e9118643f305a4c6e,

title = "COX-2 expression in highly aggressive thyroid malignancies - indication for a possible therapeutic option?",

abstract = "Both anaplastic thyroid carcinoma (ATC) and angiosarcoma of the thyroid (AST) are highly aggressive malignancies with very limited therapeutic options. Since selective inhibition of COX-2, for example, by celecoxib has been shown to suppress both tumour formation and progression, we investigated COX-2 protein expression in a series of ATC and AST (26 cases each) using immunohistochemistry. COX-2 expression was demonstrated in 13 ATC (50%) and 11 AST (42%); a strong COX-2 expression in more than 50% of vital tumour cells was found in 5 ATC and 5 AST, respectively. Although a recently performed phase II trial applying celecoxib failed overall to halt tumour progression in differentiated thyroid carcinoma, the two cases with partial or complete remission noted in this study were related to tumours with immunohistochemically proven strong COX-2 expression. The strong COX-2 expression observed in approximately 20% of our ATC and AST samples may thus indicate selective patients with a possible therapeutic option for an otherwise fatal disease.",

keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Retrospective Studies, Carcinoma genetics, Cyclooxygenase 2 genetics, Gene Expression, Hemangiosarcoma genetics, Thyroid Neoplasms genetics, Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Retrospective Studies, Carcinoma genetics, Cyclooxygenase 2 genetics, Gene Expression, Hemangiosarcoma genetics, Thyroid Neoplasms genetics",

author = "S-Y Sheu and F Grabellus and S Schwertheim and K Mann and C Ensinger and D Ofner and Maximilian Bockhorn and D Fuhrer and Schmid, {K W}",

year = "2009",

language = "Deutsch",

volume = "41",

pages = "314--319",

journal = "HORM METAB RES",

issn = "0018-5043",

publisher = "Georg Thieme Verlag KG",

number = "4",